Brass Tacks featured in Health Reporter
Understanding how a drug or therapy affects a variety of demographic groups is essential to ensuring that the product is safe and effective for everyone. However, the industry still struggles to include a broader range of people in clinical trials.
To find out what steps companies can take to ensure inclusivity and diversity, we spoke with Eileen Faucher, founder of Brass Tacks Health, a consulting firm that helps biotech and pharmaceutical companies deliver quality treatments to patients around the world.
In this interview, she shares her journey and insights on how best to ensure the success of drug development initiatives, the importance of diversity in research and testing, and her vision for the future of Brass Tacks Health.
Read the interview here.
About The Author
Dr. Eileen Faucher is the Founder & Principal of Brass Tacks Health, a boutique consulting team that provides biotech and pharma clients with original insights into their competitive clinical development landscapes, grounded in perspectives that reflect the diversity of the patient populations being served. We guide clients in how to build their competitive advantage by tapping into their organization's commitment to advancing health equity and inclusion.